Pfizer (PFE) is Resumed by Goldman to Neutral, Price Target at $35

Pfizer (PFE) was Resumed by Goldman to “Neutral” and the brokerage firm has set the Price Target at $35. Goldman advised their investors in a research report released on Apr 18, 2016.

Many Wall Street Analysts have commented on Pfizer. JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Pfizer closed down -0.15 points or -0.46% at $32.5 with 3,52,74,322 shares getting traded on Friday. Post opening the session at $32.65, the shares hit an intraday low of $32.3 and an intraday high of $32.785 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Aug 3, 2015, Loretta V Cangialosi (Sr. Vice President, Controller) sold 24,704 shares at $35.65 per share price. According to the SEC, on Jun 12, 2015, Laurie J Olson (Executive Vice President) sold 26,000 shares at $34.38 per share price. On Jun 2, 2015, Charles H Hill (Executive Vice President) sold 42,870 shares at $34.92 per share price, according to the Form-4 filing with the securities and exchange commission.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.


Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.